Therapeutic Mechanisms and Clinical Effects of Glucagon-like Peptide 1 Receptor Agonists in Nonalcoholic Fatty Liver Disease

Han Ah Lee, Hwi Young Kim

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations

Abstract

Nonalcoholic fatty liver disease (NAFLD) can lead to liver fibrosis and cirrhosis. Recently, glucagon-like peptide 1 receptor agonists (GLP-1RAs), a class of drugs used to treat type 2 diabetes and obesity, have shown therapeutic effects against NAFLD. In addition to reducing blood glucose levels and body weight, GLP-1RAs are effective in improving the clinical, biochemical, and histological markers of hepatic steatosis, inflammation, and fibrosis in patients with NAFLD. Additionally, GLP-1RAs have a good safety profile with minor side effects, such as nausea and vomiting. Overall, GLP-1RAs show promise as a potential treatment for NAFLD, and further studies are required to determine their long-term safety and efficacy.

Original languageEnglish
Article number9324
JournalInternational Journal of Molecular Sciences
Volume24
Issue number11
DOIs
StatePublished - Jun 2023

Bibliographical note

Funding Information:
This study was supported by the National Research Foundation of Korea (NRF) grant funded by the Ministry of Science and ICT (Grant nos. 2022R1I1A1A01065244, 2018R1A5A2025286) and a fund from the research program of the Korea Medical Institute.

Publisher Copyright:
© 2023 by the authors.

Keywords

  • diabetes
  • liraglutide
  • nonalcoholic steatohepatitis
  • semaglutide
  • tirzepatide

Fingerprint

Dive into the research topics of 'Therapeutic Mechanisms and Clinical Effects of Glucagon-like Peptide 1 Receptor Agonists in Nonalcoholic Fatty Liver Disease'. Together they form a unique fingerprint.

Cite this